Levetiracetam Therapeutic Drug Monitoring in a Large Cohort of Korean Epileptic Patients.
Korea
antiepileptic drugs
drug–drug interaction
epilepsy
levetiracetam
pharmacokinetics
therapeutic drug monitoring
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
23 Aug 2021
23 Aug 2021
Historique:
received:
12
07
2021
revised:
12
08
2021
accepted:
19
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
Levetiracetam is a new antiepileptic drug (AED) used for treating and preventing partial or generalized seizures. The usefulness of levetiracetam therapeutic drug monitoring (TDM) is related to inter- or intra-individual pharmacokinetic variability, drug interactions, and patient noncompliance. We aimed to investigate the levetiracetam TDM status in Korean epilepsy patients. Serum trough levetiracetam concentrations were measured using liquid chromatography-tandem mass spectrometry in 710 samples from 550 patients. The median (range) daily and weight-adjusted levetiracetam doses were 1500 (20-5000) mg and 25.5 (3.03-133.0) mg/kg, respectively. Patients on levetiracetam monotherapy constituted only 19.5% of the population, while 30.1% were on co-medication with valproate and 56.0% with enzyme-inducing AEDs (EIAEDs). Observed levetiracetam concentrations were widely distributed, ranging 0.8-95 mg/L, with a median of 17.3 mg/L. Levetiracetam concentrations were therapeutic, supra-therapeutic, and sub-therapeutic in 58.5% (
Identifiants
pubmed: 34451923
pii: ph14080826
doi: 10.3390/ph14080826
pmc: PMC8401685
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ther Drug Monit. 2012 Aug;34(4):440-5
pubmed: 22777154
Neuropsychiatr Dis Treat. 2008 Jun;4(3):507-23
pubmed: 18830435
Clin Chim Acta. 2014 Sep 25;436:224-36
pubmed: 24925169
Epilepsia. 2007 Nov;48(11):2111-5
pubmed: 17651416
Epilepsia. 2001 Dec;42(12):1574-9
pubmed: 11879369
Epilepsia. 2000 Oct;41(10):1276-83
pubmed: 11051122
Pharmacotherapy. 2015 Aug;35(8):e127-30
pubmed: 26242293
Ther Drug Monit. 2016 Jun;38(3):371-8
pubmed: 26913593
Neurology. 2000 Jul 25;55(2):236-42
pubmed: 10908898
Pharmacol Ther. 2000 Feb;85(2):77-85
pubmed: 10722121
Pediatr Neurol. 2010 Oct;43(4):231-5
pubmed: 20837299
Epilepsia. 2007 Jul;48(7):1351-9
pubmed: 17573925
J Pharm Pharm Sci. 2018;21(1s):149s-176s
pubmed: 30096051
Ther Drug Monit. 2007 Oct;29(5):576-83
pubmed: 17898647
Epileptic Disord. 2014 Dec;16(4):409-31
pubmed: 25515681
Clin Pharmacokinet. 2004;43(11):707-24
pubmed: 15301575
Nervenarzt. 2008 Feb;79(2):167-74
pubmed: 17701390
Pharmaceuticals (Basel). 2010 Jun 11;3(6):1909-1935
pubmed: 20640233
Seizure. 2018 Nov;62:131-135
pubmed: 30237016
Clin Pharmacokinet. 2008;47(5):333-41
pubmed: 18399714
Ther Drug Monit. 2004 Aug;26(4):375-9
pubmed: 15257066
Ther Drug Monit. 2020 Aug;42(4):626-630
pubmed: 31977751
Epilepsy Res. 2005 Mar-Apr;64(1-2):1-11
pubmed: 15823510
Epilepsia. 2000 Sep;41(9):1179-86
pubmed: 10999557
Clin Pharmacokinet. 2006;45(11):1061-75
pubmed: 17048972
Neurol India. 2012 Mar-Apr;60(2):146-9
pubmed: 22626693
Epilepsy Res. 2012 Feb;98(2-3):130-4
pubmed: 21944894
Epilepsy Res. 2002 Jan;48(1-2):77-89
pubmed: 11823112
Ther Drug Monit. 2015 Aug;37(4):437-44
pubmed: 25478905
Ther Drug Monit. 2018 Feb;40(1):130-134
pubmed: 29210977
Epilepsia. 2008 Jul;49(7):1239-76
pubmed: 18397299
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
Eur Neurol. 2005;54(1):34-8
pubmed: 16103676
Epilepsy Res. 2001 Nov;47(1-2):77-90
pubmed: 11673023
Seizure. 2014 May;23(5):371-6
pubmed: 24630809
Epilepsy Res. 2003 Feb;53(1-2):47-56
pubmed: 12576167
Ther Drug Monit. 2003 Dec;25(6):690-9
pubmed: 14639055